ABSTRACT Background: Extracts from Hoodia gordonii have been shown to decrease food intakes and body weights in animals and were proposed as a food supplement or ingredient for weight management. Objective: We assessed the safety and efficacy of a 15-d repeated consumption of H. gordonii purified extract (HgPE) relative to a placebo in humans. Design: Healthy, overweight women, who were stratified by percentage body fat, received either HgPE (n = 25) or a placebo (n = 24) for 15 d. Subjects were resident in a clinic for a 4-d run-in period and a 15-d treatment period in which they received 2 servings/d of 1110 mg HgPE or a placebo formulated in a yogurt drink 1 h before breakfast and dinner. Subjects were otherwise allowed to eat ad libitum from standardized menus. Results: There were no serious adverse events, but HgPE was less well tolerated than was the placebo because of episodes of nausea, emesis, and disturbances of skin sensation. Blood pressure, pulse, heart rate, bilirubin, and alkaline phosphatase showed significant (P , 0.05) increases in the HgPE group. Mean effects on ad libitum energy intakes and body weights did not differ significantly between the HgPE-and placebo-treatment groups (P . 0.05). Conclusions: In comparison with a matched placebo, the consumption of HgPE for 15 d appeared to be associated with significant adverse changes in some vital signs and laboratory parameters. HgPE was less well tolerated than was the placebo and did not show any significant effects on energy intakes or body weights relative to the placebo. This trial was registered at clinicaltrials. gov as NCT01306422.
INTRODUCTION
Hoodia gordonii (Masson) Sweet ex Decne is a perennial, succulent plant species from the Apocycnacaea (previously Asclepiadaceae) family that is indigenous to the arid regions of South Africa, Botswana, and Namibia (1) . An initial exploratory research with several species of Hoodia showed that H. gordonii contained steroid glycosides that decreased food intakes and body weights in animals (2) . The research indicated the efficacy of H.g.-12 and H.g.-20, which are 2 major steroid glycosides present in H. gordonii, that pointed to these steroid glycosides as potential lead appetite-suppressing components of H. gordonii. A safety study with a 13-wk repeated administration of HgPE 4 (which contained 79.3% steroid glycosides) also showed that HgPE induced significant dose-dependent reductions in food intakes and body weights in rats (SL Nicholson, A Orsi, G Salmon, CW Tam, and CL Ward, unpublished observations, 2007).
In addition to these effects of H. gordonii extracts on food intakes in rats, a previous human clinical study (J Richards and R Grover, unpublished observations, 2003) with a pharmaceutical extract of H. gordonii (which contained 79.5% steroid glycosides) showed that a 15-d repeated intake of the extract (1800 mg, given in capsules 1 h before breakfast and 1 h before dinner) reduced energy intakes by ;30% compared with those from intake of a placebo.
From this limited but supportive research evidence and very substantial anecdotal literature, extracts of H. gordonii have become widely promoted as food supplements with putative weightmanagement properties. This development has arisen despite a lack of published evidence for efficacy and safety from randomized placebo-controlled human clinical trials that used wellcharacterized material and known dose-exposures to H. gordonii.
Recent work that used a process of solid-liquid solvent extraction and purification has led to an HgPE (that contains 79.3% wt:wt steroid glycosides) being developed as a food ingredient proposed for the control of appetite and body weight (T Knight, AM Craddock, S Buchwald-Werner, S Alaoui Ismaili, VJ Maharaj, and SC MacWiliam, unpublished observations, 2006). The objective of the current study was to assess the safety, tolerability, and efficacy of 15-d repeated consumption of this extract in healthy overweight women.
SUBJECTS AND METHODS

Subjects
The study was conducted at Covance Clinical Research Unit (Madison, WI) in healthy overweight women aged 18-50 y. Respondents gave written informed consent and were accepted for participation if they were in good health (medical history, physical examination, electrocardiogram, and laboratory tests), had a stable body weight for !2 mo, and had a percentage body fat between 25% and 45% (amended from 25% to 40% during the recruitment phase) as measured by dual-energy X-ray absorptiometry. Subjects were excluded if they were pregnant, lactating, or not willing to use 2 methods of contraception from !14 d before the start of the treatment. Smokers, restrained eaters [score .16 on the revised restraint scale (3)], subjects with an overnight fasting blood glucose concentration .7 mmol/L, or subjects who were dieting were excluded from participation. Subjects who were taking prescription or over-the-counter medication (with the exception of hormonal contraceptives) or who reported metabolic or endocrine disease, gastrointestinal disorders, or a history of medical or surgical events that might have affected the study outcome were also not included in the study. With the use of a food action rating scale (4), subjects were excluded if they had a low score for acceptability of the meal plan and study product (an average score of all rated items !5, with 2 items that scored 3 and no items that scored 1). This study was conducted in accordance with the applicable US Code of Federal Regulations and Good Clinical Practice, which are consistent with the Declaration of Helsinki.
Study products
HgPE was formulated as a raspberry-flavored yogurt drink that contained 1110 mg HgPE per serving. HgPE was obtained by methanol extraction of dried whole H. gordonii plant (excluding roots), which was followed by purification steps with heptane and heptane/methyl ethyl ketone (5) . The analytic characterization and specification of the HgPE used in this study has been reported (6) . In brief, the extract consisted of a mixture of steroid glycosides (79.3% wt:wt), fatty acids, alkanes, plant sterols, and alcohols (wax esters).
The absolute bioavailability of the major steroid glycoside H.g.-12 in humans was estimated to be ;50% on the basis of animal data generated by Graf et al (7) and Madgula et al (8) . Moreover, the bioavailability in formulations tested in animal studies seemed to be meal and formulation independent (7). The pharmacokinetic profile of H.g. -12 showed that H.g.-12 is rapidly absorbed and cleared from blood plasma (PC van der Pijl, WAM Blom, CL Ward, W Wang, SL Abrahamse, and GSMJE Duchateau, unpublished observations, 2008). H. gordonii steroid glycoside metabolites have been identified and described by van Platerink (9) and van Platerink et al (10) ; the most abundant metabolites in plasma are the detiglated steroid glycosides.
Unpublished studies with a pharmaceutical-grade extract of H. gordonii (which contained 79.5% steroid glycosides) indicated that reductions in energy intakes in humans were associated with a C max of a marker steroid glycoside (H.g.-12 equivalents) of 100 ng/mL. In a series of preliminary clinical studies (data not shown), it was shown that this target plasma concentration was achieved with the dose amount of 1110 mg HgPE per serving.
HgPE was dissolved in the diglyceride-rich oil, and the solution was deodorized for 5 h at 120°C. Pectin and sugars and sweeteners were dissolved in water, and yogurt was added, followed by colorants, flavors, and the deodorized solution of HgPE in oil. The yogurt-drink products were homogenized and pasteurized, which resulted in a stable oil-in-water emulsion. Samples of study products analyzed for their steroid-glycoside content confirmed that these active components survived the process (6) . The placebo product was closely matched in taste and appearance. Both study products had a similar nutritional composition ( Table 1 ). All study products were manufactured at Unilever Research & Development facilities.
Study design
This was a randomized, double-blind, placebo-controlled, parallel-group study. Subjects were admitted to the clinic for a 19-d residential period. During a 4-d run-in period, all subjects received no study product on study day 24 and only a placebo during study days 23 to 21 (single blind). Subjects were assigned either to receive the HgPE-formulated product or to continue with the placebo product on study days 1 to 15 (double blind). Subjects left the clinic at study day 16, 21 h after the last study-product consumption and returned for follow-up visits on study days 17, 22, and 37. Subjects were instructed to abstain from alcohol and grapefruit-containing foods or beverages (11) (12) (13) for 72 h before study day 24 and during the remainder of the study, including the follow-up, and to abstain from strenuous exercise during the study period.
At each study-product administration (1 h before breakfast and 1 h before dinner), subjects were instructed to consume the entire contents of the bottle in one intake through a straw within 2 min and immediately drink 150 mL H 2 O. Subjects were offered 300 mL of noncaloric beverages with breakfast (0905), lunch (1310), dinner (1700), and snack (2100). Subjects were allowed to drink water ad libitum throughout the day and noncaloric beverages ad libitum after the evening snack.
During all 19 d of the clinic stay, subjects had no access to external food sources and consumed only food and beverages that were provided to them by the study personnel. Meals were eaten ad libitum from standardized menus on a 5-d rotating meal plan (see Supplement 1 under "Supplemental data" in the online issue). Meals were presented in larger portions than would ordinarily be consumed (eg, a 1250-g entrée, 300-g side dish, and 750-g dessert), and subjects could request more food. Subjects ate individually (ie, they could not see each other eating and were instructed not to talk during the meal).
Energy densities (kcal/g) of all foods offered during a given meal were closely matched so that the overall energy intake would be determined almost entirely by the weight of foods consumed and not by specific preferences and choices. Subjects had a choice between 4 breakfasts with similar energy densities. Lunch and dinner consisted of an entrée, side dish, and dessert, all of which had similar energy densities. Furthermore, overall energy densities of all 5 lunches and all 5 dinners were similar. In the evening, subjects could choose from a range of snacks with similar energy densities. Meals were prepared by Gaylord's Catering Service (Madison, WI).
Randomization and blinding
Subjects were stratified by percentage body fat and were randomly assigned to receive HgPE or a placebo treatment. Randomization (which was generated by a computer with a random seed chosen from a table of random numbers) was performed by the clinical facility, which also generated emergency code break envelopes that were kept by the clinical study director, together with a log of people who were unblinded. Only the statistician and persons responsible for labeling were unblinded. Treatment allocations were concealed from the study staff and subjects, and thus, days 1-15 were double blind. Study staff, but not subjects, knew that all subjects received a placebo during the run-in period, and thus days 23 to 21 were single blind.
Unblinding
This study was partially unblinded at the request of Unilever because the number and type of AEs reported were considered unusual and unanticipated for a food product. Although these AEs, such as a disturbance of skin sensation, did not appear to be an immediate danger to subjects, it was judged to be in the best interest of subject safety to assess these immediately. A physician, a toxicologist, and a statistician who were independent from the test facility viewed the partially unblinded data to assess the pattern, severity, and effect of AEs. The allocation to group was revealed to these 3 individuals, but the identity of the treatment was not. The investigator and other clinical staff remained blinded to subject randomization. After independent review of these data, the recommendation was to continue dosing all subjects.
Safety parameters
The timing of all safety and efficacy assessments are presented in Table 2 . Safety assessments included AEs, a physical examination, vital signs, electrocardiograms, and laboratory assessments.
AEs were recorded spontaneously, and subjects were questioned indirectly on every study day. An AE was any event that changed the patient's well-being, whether or not it was related to the investigational products. AEs were classified as treatment emergent (a TEAE) whenever they occurred in either the placebo run-in or double-blind treatment period. All AEs were coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (14) .
All electrocardiograms were performed with a Mac 1200 ECG machine (GE Healthcare) after subjects were supine for !5 min. Vital signs (systolic and diastolic blood pressure and pulse) were measured after the subject had been seated for 5 min.
The following safety laboratory assessments were performed at Meriter Laboratories Inc (Madison, WI): the serum chemistry panel included fasted samples for creatinine, total bilirubin, direct bilirubin, indirect bilirubin, ALP, ALT, aspartate aminotransferase, c-glutamyl transferase, sodium, potassium, bicarbonate, creatine phosphokinase, BUN, total protein, glucose, insulin, chloride total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides; the hematology panel included fasted samples for hemoglobin, haptoglobin, hematocrit, erythrocytes, platelets, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cell distribution width, and leukocyte count; and urinalysis included appearance, glucose, ketones (qualitative), hemoglobin (qualitative), protein, nitrite, bilirubin, specific gravity, pH, urobilinogen, and microscopic examination.
Efficacy parameters
A food consumption record detailed the food item selected and the timing and weight of all food items as given to each subject EFFECTS OF H. gordonii ON SAFETY AND ENERGY INTAKE and returned by them uneaten. Energy intake was calculated from the weight consumed and the energy density of the food item.
Body weight was measured after an overnight fast, after voiding, before study-product administration. Dual-energy X-ray absorptiometry (Lunar Prodigy Advance; GE Healthcare) was used to estimate fat mass and lean body mass.
Plasma pharmacokinetic analysis of Hoodia steroid glycoside
Blood samples for analysis of plasma concentrations of the steroid glycoside H.g.-12 equivalents were collected frequently (20 samples/d) on study days 1 and 15 to allow the construction of curves of full concentration compared with time. On study days 5 and 10, 5 samples were collected, divided over the day (including a sample around C max ) to confirm plasma concentration profiles. On all other study days up to day 16, a fasting-state sample was taken before the first study-product administration. In addition, samples were collected at follow-up (days 17, 22, and 37).
In this study, H.g.-12 equivalents were measured in blood plasma (Quotient Bioresearch) as markers for exposure to the HgPE. Plasma concentration results derived from the study samples were reported as H.g.-12 equivalents because shoulder peaks to the main H.g.-12 peak were present in the chromatographic method used (15) , and these were considered to be due to the presence of epimers of H.g.-12.
Pharmacokinetic calculations were performed with WinNonlin software (version 5.2; Pharsight Corp) with the assumption of a one-compartment model with no lag time and first-order elimination. Parameters were calculated for both test-product servings on study days 1 and 15. For each subject, the C max , time to C max , AUC, and t 1/2 were estimated from plasma concentration data.
Statistical analyses
The study was designed to detect a treatment difference of 450 kcal or 20% reduction in energy intake on the basis of an SD of this difference of 548 kcal (on the basis of data from J Richards and R Grover, unpublished observations, 2003) with a power of 0.8 and significance level of 0.05, which was one sided (only a reduction compared with the placebo was considered a relevant result). A minimum of 20 subjects per group were required to achieve this level of statistical power.
Safety analyses were conducted on the data from the safety population (n = 49), which included all subjects who were randomly assigned into the study. Efficacy analyses were conducted on the data from the PP population (n = 42). The PP population included all subjects who completed all study procedures from days 24 to 16 or had taken !27 study products (of a total of 30 study products) and for whom there were no major protocol deviations.
For electrocardiograms, vital signs, and laboratory data, the statistical analysis was performed on day-15 or -16 data (if day-15 data were not available), using an ANCOVA with treatment as a fixed effect and baseline as a covariate. The baseline was Body weight
day 24 or the first available measurement before the first dosing (if the measurement on day 24 was not taken). Parameters with treatment P values , 0.10 were also examined with a repeatedmeasure ANCOVA with treatment, day, and treatment-by-day interaction as fixed effects and baseline as a covariate. Measurements taken on all days after the first dosing were assessed in this analysis.
AEs were summarized descriptively. The planned chi-square test or Fisher's exact test for comparison between treatment groups was deemed unnecessary.
The baseline energy intake was determined by calculating the mean intake during the run-in period (days 23, 22, and 21). The energy intake at the end of the intervention (ie, the mean of days 13-15) was modeled with baseline energy intake as a covariate plus the treatment effect (for the day total only) as follows:
Mean
The same model was used for body weight. For estimates of differences from these models, SEs were reported, whereas for mean values, SDs were reported. Differences from baseline, where mentioned, were calculated by paired t tests.
An ANOVA model with the subject as a random factor and study day (day 1 compared with day 15), serving (breakfast compared with dinner), and their interaction as fixed factors was performed for the log-transformed AUC, the log-transformed C max , and t 1/2 of H.g.-12 equivalents in plasma. AUC and C max data were log transformed because of skewed residuals.
Statistical calculations for safety parameters were performed with SAS software (version 9.1; SAS Institute Inc). The statistical calculations for efficacy parameters were performed in the statistics package R (Foundation for Statistical Computing) (16) with the add-on package multcomp (17) for tests of hypotheses; when appropriate, the statistical calculations for the pharmacokinetic parameters were performed with JMP software (version 9.0.2, SAS Institute Inc).
RESULTS
Of 116 individuals assessed for eligibility, 49 subjects were randomly assigned into the study (Figure 1) . The first subject was enrolled on 6 March 2008, and the last subject completed the study on 28 July 2008. Subject demographics are presented in Table 3 . Forty-one subjects completed the study; 8 subjects were withdrawn early from the study for the following reasons: AEs [emesis in 2 subjects (both HgPE) and 1 subject with an allergic reaction (placebo)]; withdrawal of consent [3 subjects (all HgPE)]; and 2 subjects for other reasons [difficult venipuncture (placebo) and intolerance to study product (during placebo run-in)].
Safety
AEs
A summary of AEs is presented in Table 4 . There were no severe or serious AEs reported throughout the study, and most AEs were mild (335 AEs were mild compared with 19 moderate AEs). In general, the number of TEAEs reported in the HgPE group was higher than in the placebo group (208 compared with 69 TEAEs, respectively). This result indicated that HgPE was less well tolerated than was the placebo. The most common TEAEs were a disturbance of skin sensation, headache, dizziness and giddiness, and nausea ( Table 5 ). An independent neurologist assessed 4 of the subjects who reported disturbances in skin sensation. In the absence of neurologic abnormalities and given the transitory nature of symptoms, these symptoms were deemed most likely to be a study-product effect. When the study was unblinded, all of these subjects were shown to be in the HgPE group. 
EFFECTS OF H. gordonii ON SAFETY AND ENERGY INTAKE
Electrocardiograms
All electrocardiograms were determined by the investigator to be either normal or abnormal but not clinically significant.
Statistical analysis of the electrocardiogram data by using repeated-measures ANCOVA showed that the PR interval in the HgPE group was statistically significantly (P , 0.05) higher on day 22 and from days 1-16 (mean difference ranged from 6.3 to 22.9 ms) than that with the placebo. The HgPE group also showed significantly (P , 0.05) higher ventricular heart rate from days 22 through 17 (mean difference ranged from 4.8 to 12.4 beats/min) and a significantly (P , 0.05) lower QT interval on days 21 and 2-17 (mean difference ranged from 13.0 to 21.6 ms) than did the placebo group. The QRS and QTcB intervals were also significantly (P , 0.05) higher from days 2-15 in the HgPE group than those in the placebo group, but in the evening only (mean difference ranged from 2.5 to 6.1 and 6.4 to 13.7 ms, respectively).
Vital signs
The HgPE group had significantly (P , 0.05) higher systolic blood pressure (mean difference ranged from 5.9 to 15.9 mm Hg) on days 2-16 than did the placebo group (Figure 2) . Diastolic blood pressure was significantly (P , 0.05) higher for the HgPE group than for the placebo group (mean difference ranged from 4.6 to 11.5 mm Hg) from days 2 to 14 (P , 0.05). Also, the pulse was significantly (P , 0.05) higher in the HgPE group than in the placebo group from days 2 to 11 and on day 14 (mean difference ranged from 5.2 to 9.9 beats/min).
Safety laboratory results
In the HgPE group, total, indirect, and direct bilirubin values at the end of treatment (day 15) were significantly higher than in the placebo group (P , 0.05). Repeated-measures ANCOVA showed that total and indirect bilirubin values in the HgPE group were significantly (P , 0.05) elevated from days 2 to 17 (mean difference ranged from 0.20 to 0.58 mg/dL and 0.18 to 0.49 mg/ dL, respectively) ( Figure 3 ). This elevation was not noted in the placebo group. Direct bilirubin values were significantly (P , 0.05) higher from days 2 to 16 (mean difference ranged from 0.04 to 0.09 mg/dL) than those with the placebo.
In the HgPE group, ALP values at the end of treatment (day 15) were significantly (P , 0.05) higher than those with the placebo. Repeated-measures ANCOVA showed that ALP values in the HgPE group were significantly (P , 0.05) elevated from days 8 to 17 (mean difference ranged from 4.7 to 8.8 U/L). BUN values at the end of treatment were significantly (P , 0.05) lower in the HgPE group than in the placebo group. BUN values in the HgPE group were significantly (P , 0.05) decreased from days 2 to 17 (mean difference ranged from 1.3 to 2.7 mg/dL). There were no significant differences noted in creatinine, c-glutamyl transferase, aspartate aminotransferase, and ALT between the HgPE and placebo group. (8) 134 (20) 10 (6) 27 ( 
Efficacy
Energy intake
Energy intake values are shown in Figure 4 . Energy intake at the end of treatment, as assessed by calculating the mean daily energy intake on study days 13-15, which were corrected for baseline, did not differ significantly [absolute difference (6SE): 121.3 6 96 kcal; P = 0.214] between the HgPE group and the placebo group. In both the HgPE and placebo group, a marked decline in the mean energy intake was apparent by study days 3-5. This reduced intake was maintained for the duration of the treatment period in both groups and was seen at all meal occasions. The energy intake at the end of treatment was significantly (P , 0.05) reduced by ;18% in the placebo group and ;24% in the HgPE group compared with at baseline.
Body weight
The mean body weight at the end of treatment, which was corrected for baseline, did not differ significantly between the (11) 2 (2) 11 (6) (4) 13 (11) 5 (4) 17 (9) 45 (28) Complications of medical care, not elsewhere classified 10 (4) 12 (10) 5 (4) 16 (9) 43 (27) Diseases of the musculoskeletal system and connective tissue 0 (0) 9 (8) 4 (2) 8 (7) 21 (16) Pain in limb 0 (0) 6 (5) 4 (2) 8 (7) 18 ( (1) 2 (1) 5 (5) 8 (7) Aspiration of fluid or tissue, puncture, and catheterization 0 (0) 1 (1) 2 (1) 5 (5) 8 ( . A repeated-measures ANCOVA showed that systolic blood pressures were significantly (P , 0.05) higher from days 2 to 16 (mean difference ranged from 4.6 to 11.5 mm Hg) in the HgPE group than in the placebo group. Diastolic blood pressures were significantly (P , 0.05) higher from days 2 to 14 (mean difference ranged from 5.9 to 15.9 mm Hg) in the HgPE group than in the placebo group. The dosing period is shaded. HgPE, Hoodia gordonii purified extract. placebo or HgPE groups (absolute difference: 0.08 kg 6 0.39 kg). The 15-d repeated consumption of placebo or HgPE resulted in significant (P , 0.001) reductions in body weight of 1.2 6 1.2 and 1.2 6 1.3 kg, respectively, compared with at baseline. During the follow-up period, mean body weights returned to baseline (baseline for placebo: 69.2 6 8.7 kg; baseline for Hoodia: 66.4 6 8.5 kg; day 37 for placebo: 69.5 6 8.9 kg; day 37 for Hoodia: 66.8 6 8.9 kg).
Percentage body fat
The 15-d repeated intake of HgPE or placebo had no significant effect on percentage body fat; values for the placebo and HgPE groups were 37.4 6 5.6% and 36.0 6 5.5%, respectively, at baseline (day 21) and 37.4 6 5.9% and 36.3 6 6.1%, respectively, at the end of treatment (study day 16). Therefore, weight loss was equally distributed over fat mass and lean body mass.
Pharmacokinetics of Hoodia steroid glycoside
Pharmacokinetic parameters calculated for the H.g.-12 equivalents are presented in Table 6 . In general, the interindividual variation in the AUC and C max was large and differed to a factor 10. C max values were slightly lower after the first breakfast serving on day 1 and reached a mean concentration of 92 6 47 ng/mL, whereas mean C max concentrations after the other servings reached concentrations .100 ng/mL. However, an ANOVA analysis showed no significant effect of study day (P = 0.11) or serving (breakfast compared with dinner; P = 0.82) on the logtransformed C max . The time to reach C max was ;45-50 min, with elimination rates (t 1/2 ) of ;50 min. The mean area under the total curve (doses 1 and 2) was 366 6 175 ng Á mL 21 Á h 21 on day 1 compared with 439 6 228 ng Á mL 21 Á h 21 on day 15. The results of the ANOVA analysis suggested that study day (day 1 compared with day 15) may have been relevant for the log-transformed AUC (P = 0.06). Statistical analyses were performed in 21 subjects who were randomly assigned to the placebo group and in 19 subjects who were randomly assigned to the HgPE group. HgPE, Hoodia gordonii purified extract. 
DISCUSSION
This study showed that repeated the consumption of HgPE over a 15-d period under highly controlled conditions had no significant effects on ad libitum energy intake, body weight, or percentage body fat in healthy overweight women relative to the consumption of a matched placebo. There were no serious AEs, but HgPE was less well tolerated than the placebo and produced adverse changes in some clinical measures.
The pharmacokinetic results from this study showed that HgPE was rapidly absorbed, and the target C max of 100 ng/mL of the H.g.-12 marker was met in the current study. The dose of 1110 mg HgPE 2 times/d used here was physiologically relevant because significant changes in blood pressure, heart rate, PR and QT intervals, and bilirubin, ALP, and BUN concentrations were induced compared with those with consumption of the placebo. However, it was not possible to confirm whether these adverse physiologic changes were caused by Hoodia steroid glycosides or, perhaps, by uncharacterized substances in the extract (,9.4% of total).
The clinical significance of changes in bilirubin and ALP was unclear because subjects had no other elevations in liver enzymes or evidence of hemolysis. However, the trend for bilirubin values to increase over time in the HgPE group, which returned to normal after treatment was finished, was similar to the finding in a previous human study with a pharmaceutical grade extract (J Richards and R Grover, unpublished observations, 2003). It is also known that bilirubin increase can be associated with prolonged fasting (18) (19) (20) ; however, no corresponding change in bilirubin was seen in the placebo group despite a similarly reduced food intake. Therefore, it seems probable that this effect on bilirubin was a direct effect of the HgPE, but this possibility needs further investigation.
It is clear that the HgPE group had a much higher incidence of TEAEs and a higher number of withdrawals compared with those in the placebo group, despite similar weight loss for both groups. These results suggested that AEs reported in the HgPE group could be only partly explained by weight loss. Furthermore, a neurological assessment of reported disturbances in skin sensation indicated that these were most likely a study-product effect, and all affected subjects were in the HgPE group.
Although HgPE induced a number of physiologically relevant changes in this study, its effects on energy intake and body weight did not differ from those with the placebo. On average, subjects in both treatment groups were in a negative energy balance of ;500 kcal/d over the 15-d treatment period, which was consistent with the observed mean change in body weight of ;1.2 kg in both groups during this time.
The statistical power calculation for this study was based on achievement of a 20% difference in energy intake between HgPE and placebo groups. The actual statistical power was much greater than anticipated because the SD of the treatment difference in energy intake was smaller than expected. Therefore, the lack of significant differences in energy intakes was not due to a lack of power but reflected the small effect size.
Overweight subjects have previously been shown to exhibit a tendency to decrease their energy intakes below requirements under restricted conditions such as those experienced in this study (21, 22) . Therefore, it is plausible that subjects were intentionally dieting during the 15-d treatment, even though the screening for dietary restraint and dieting had been intended to exclude subjects highly concerned about their weight or prone to dieting. Given the reduction in energy intake also seen in the placebo group, the efficacy in the HgPE group might have been more readily demonstrable if subjects experienced less feelings of hunger at this same amount of caloric deprivation. However, the analysis of self-reported hunger and satiety data (data not shown) also did not indicate any treatment differences over the course of the trial. Another potential factor could have been the knowledge by subjects that their food intakes and body weights were being measured, which led to the conscious or unconscious inhibition of food consumption and resulted in weight loss.
Undereating can also be induced by meals being too low in energy content or energy density (23); however, the energy densities of food products in the current study were within normal ranges. The average total energy density for meals and test products eaten in this study at baseline was 1.5-1.6 kcal/g (breakfast: 1.1 6 0.1 kcal/g; lunch: 1.3 6 0.03 kcal/g; dinner: 1.6 6 0.04 kcal/g; snack: 4.4 6 0.12 kcal/g; study product: 0.58 kcal/g). A typical reported total diet energy density, excluding beverages, in subjects who were studied outside of a residential environment was 1.3-1.8 kcal/g (24, 25) . Any effect of low energy density on energy intakes would also have been expected to be most apparent in the immediate run-in period, but this effect was not seen. Subjects with low acceptance of the foods provided were excluded from participation; therefore, it was unlikely that the foods were unacceptable or unpalatable to the volunteers. However, the repetition of meals and the lack of variability in types of meals may have induced some degree of boredom or sensory specific satiety and reduced the liking or wanting of meals as the study proceeded (26) . Several of the AEs reported by subjects in this study, such as dizziness, giddiness, nausea, and vomiting, could also have reduced appetite and, therefore, reduced energy intake. However, these AEs were predominantly reported by the HgPE group, and incidences of nausea and vomiting were not clearly linked with changes in energy intakes.
It is also conceivable that a serving size of 2220 mg HgPE/d was not sufficient to induce additional effects on energy intakes. The maximum average concentration of the H.g.-12 equivalents in blood plasma reached the target concentration of 100 ng/mL; however, the interindividual variation in C max was quite large (values ranged between 15 and 355 ng/mL) with concentrations far above the concentrations of 100 ng/mL reached in some subjects. Because of the rapid absorption and elimination characteristics of H.g.-12 equivalents, resulting plasma concentration profiles may not be ideal to achieve energy-intake reductions. However, without a more complete understanding of the mechanism and site of action, it is difficult to define whether plasma C max or exposure is more important. Despite this, there was no clear correlation between the H.g.-12 equivalent C max or AUC and efficacy (data not shown). Furthermore, given the observed AEs and changes in clinical measures at the current dose amount, the tolerability and safety of higher intakes or other patterns of consumption would need to be carefully considered.
In conclusion, the totality of data from this study did not provide evidence of efficacy in terms of a reduction in energy intakes and body weights in the HgPE treatment group relative to in the placebo-treatment group. There were no differences in effects at different meal occasions (eg, at breakfast or dinner) and no consistent relations between markers of Hoodia exposure (ie, C max and AUC) and reductions in energy intake. HgPE was less well tolerated than the placebo and significantly affected some clinical and safety parameters, such as blood pressure, bilirubin, and electrocardiogram measures. There are many commercially available dietary supplements that claim to contain H. gordonii. Given the results here, we cannot exclude the possibility that consumers who take certain of these supplements could experience similar side effects. More knowledge of the mechanisms, sites of action, and active components of HgPE is required before a final conclusion can be drawn regarding the potential use of HgPE as a viable-candidate functional food ingredient targeted at aiding weight management.
